A study evaluating efficacy of noadjuvant Doxorubicin and Cyclophosphamide followed by Paclitaxel with Trastuzumab and Pertuzumab in patients with HER2‐positive early stage breast cancer
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 14 Dec 2019 Results (N=236), assessing disease free survival rate, presented at the 42nd Annual San Antonio Breast Cancer Symposium.
- 13 Feb 2018 New trial record